These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23318602)

  • 21. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a.
    Ferenci P; Formann E; Romeo R
    Am J Gastroenterol; 2005 Jul; 100(7):1626-7. PubMed ID: 15985000
    [No Abstract]   [Full Text] [Related]  

  • 22. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
    Goulis I; Karatapanis S; Akriviadis E; Deutsch M; Dalekos GN; Raptopoulou-Gigi M; Mimidis K; Germanidis G; Drakoulis C; Triantos C; Zintzaras E; Bakalos G; Papatheodoridis G
    Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months.
    Ormeci N; Bölükbaş F; Erden E; Coban S; Ekiz F; Erdem H; Palabıyıkoğlu M; Beyler AR; Balık I; Bölükbaş C; Nazlıgül Y; Köklü S
    Hepatogastroenterology; 2011; 58(110-111):1648-53. PubMed ID: 22086695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.
    Perrillo RP
    Hepatology; 2009 Apr; 49(4):1063-5. PubMed ID: 19330864
    [No Abstract]   [Full Text] [Related]  

  • 29. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
    Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 38. [Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].
    Yu HB; Ma LN; Liu YL; Hua W; He ZM; Lu JF; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):895-8. PubMed ID: 24636289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
    [No Abstract]   [Full Text] [Related]  

  • 40. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.